1 week Ago By Defense World Staff
Bank of Montreal Can purchased a new position in Inovio Pharmaceuticals, Inc. ( NASDAQ:INO – Free Report ) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 23,495 shares of the biopharmaceutical company’s stock, valued at approximately $43,000.
Bank of Montreal Can owned approximately 0.09% of Inovio Pharmaceuticals at the end of the most recent reporting period. A number of other hedge funds also recently modified their holdings of INO.
Geode Capital Management LLC raised its stake in shares of Inovio Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after purchasing an additional 6,874 shares during the period.
AIGH Capital Management LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at approximately $1,197,000. Highbridge Capital Management LLC acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $549,000. Wolverine Asset Management LLC bought a new position in shares of Inovio Pharmaceuticals during the 4th quarter worth approximately $178,000.
Finally, Green Alpha Advisors LLC raised its holdings in shares of Inovio Pharmaceuticals by 103.2% in the fourth quarter. Green Alpha Advisors LLC now owns 65,446 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 33,232 shares during the last quarter.
Institutional investors and hedge funds own 26.79% of the company’s stock. Analyst Upgrades and Downgrades A number of research firms recently weighed in on INO.
HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. StockNews.
com upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, April 17th. Royal Bank of Canada dropped their target price on Inovio Pharmaceuticals from $6.00 to $5.
00 and set a “sector perform” rating on the stock in a report on Wednesday, March 19th. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th.
Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $12.
20. Inovio Pharmaceuticals Stock Performance Inovio Pharmaceuticals stock opened at $1.87 on Friday.
The stock has a 50-day simple moving average of $1.84 and a 200 day simple moving average of $2.88.
The stock has a market capitalization of $68.58 million, a P/E ratio of -0.47 and a beta of 1.
84. Inovio Pharmaceuticals, Inc. has a 52 week low of $1.
42 and a 52 week high of $13.44. Inovio Pharmaceuticals ( NASDAQ:INO – Get Free Report ) last posted its earnings results on Tuesday, March 18th.
The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.
18. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.
03 million. Research analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.
23 earnings per share for the current year. Inovio Pharmaceuticals Company Profile ( Free Report ) Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Read More Five stocks we like better than Inovio Pharmaceuticals 3 Small Caps With Big Return Potential Markets Think Robinhood Earnings Could Send the Stock Up How to Use the MarketBeat Stock Screener Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? What is a Secondary Public Offering? What Investors Need to Know AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. ( NASDAQ:INO – Free Report ).
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
